A plan to access cheap drugs backfires, leaving patient with $250,000 bill

What To Know

This article describes one patient's experience with employer-directed "alternative funder" programs that attempted to access drugmaker charity or assistance supplies for costly medicines. The patient, who has Crohn's disease, received vedolizumab (Entyvio) infusions but later faced a large bill after the funding arrangement collapsed.

The piece explains how some employers and middlemen try to reduce pharmacy costs by steering patients to manufacturer assistance, and how tightened manufacturer rules can leave patients unexpectedly responsible for charges. The article is a patient-focused news report, not a clinical study.

It highlights the financial and treatment-access risks when employers use third parties to secure charity or subsidized medication supplies. It quotes clinicians and mentions regulatory attention from U.S. lawmakers and the Department of Labor.

If you're reading this because of similar billing or coverage problems, this story illustrates why it's important to confirm with your insurer and treatment team who is responsible for coverage before starting costly therapies, and to keep records of communications with benefit managers and third-party vendors.